SCHEDULE: TD Bank and TD Securities Report UroGen Pharma Stake

The Toronto-Dominion Bank and TD Securities Inc. have jointly filed a Schedule 13G, reporting a combined beneficial ownership of 5.9% in UroGen Pharma Ltd.

Summary

• The Toronto-Dominion Bank (TD Bank) and its subsidiary TD Securities Inc. (TDSI) have filed an amendment to their Schedule 13G filing.
• This filing indicates their beneficial ownership of UroGen Pharma Ltd. ordinary shares.
• TD Bank beneficially owns 2,770,530 shares, representing 5.7% of the class.
• TDSI beneficially owns 115,706 shares, representing 0.2% of the class.
• The total combined beneficial ownership reported is 2,886,236 shares, or 5.9% of the class.
• TD Bank is the sole owner of TDSI and may be deemed to hold an indirect interest in the shares reported by TDSI.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral to slightly negative score due to the nature of a Schedule 13G filing, which primarily reports passive ownership stakes rather than active strategic developments or performance indicators.

Positives

• The filing confirms a significant, albeit passive, stake held by major financial institutions in UroGen Pharma.
• TD Bank has sole voting and dispositive power over its 2,770,530 shares.
• TDSI has sole voting and dispositive power over its 115,706 shares.

Negatives

• The filing is a Schedule 13G, indicating passive investment rather than active engagement or strategic partnership.
• TD Bank disclaims ownership of TDSI's shares except to the extent of its pecuniary interest, suggesting a limited direct control.

Risks

• The filing does not disclose any specific risks related to UroGen Pharma's business operations or financial performance.
• The primary risk is that the passive nature of the investment by TD Bank and TDSI means they are not actively involved in the company's strategic direction or governance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding UroGen Pharma's future performance. It solely reports on the ownership stake of TD Bank and TD Securities Inc.

Management Comments

• Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) of the US Securities Exchange Act of 1934 or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate or other group for the purpose of acquiring, holding or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for large financial institutions that acquire significant stakes in companies for investment purposes, often without seeking control. This filing places UroGen Pharma within the portfolio of major financial players like TD Bank.

Stakeholder Impact

• Shareholders: The filing indicates increased institutional interest, which could be perceived positively, but the passive nature of the stake suggests no immediate impact on corporate strategy or governance.
• Creditors: No direct impact is indicated as the filing pertains to equity ownership.
• Employees: No direct impact is indicated as the filing pertains to equity ownership.

Next Steps

• The reporting persons will continue to hold their shares in UroGen Pharma Ltd. in the ordinary course of business.
• Future amendments to this Schedule 13G will be filed if there are material changes in ownership.

Key Dates

Keywords

UroGen Pharma, Schedule 13G, beneficial ownership, The Toronto-Dominion Bank, TD Securities Inc., ordinary shares, passive investment